Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE24.1350
- TODAY'S CHANGE (%)0.0850 (0.3534%)
- Bid / Lots24.0500/ 8
- Ask / Lots24.2200/ 8
- Open / Previous Close24.8000 / 24.0500
- Day Range
- 52 Week Range
- Volume97,644
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 15902 | 24.22 |
| 09:33 ET | 10657 | 24.86 |
| 09:35 ET | 1293 | 24.84 |
| 09:37 ET | 4597 | 24.905 |
| 09:39 ET | 2050 | 24.99 |
| 09:42 ET | 2101 | 25 |
| 09:44 ET | 3685 | 24.56 |
| 09:46 ET | 945 | 24.45 |
| 09:48 ET | 2445 | 24.4675 |
| 09:50 ET | 5883 | 24.51 |
| 09:51 ET | 1300 | 24.41 |
| 09:53 ET | 4799 | 24.395 |
| 09:55 ET | 2150 | 24.32 |
| 09:57 ET | 7012 | 24.29 |
| 10:00 ET | 4020 | 24.24 |
| 10:02 ET | 912 | 24.135 |
Nov 12, 2024
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
5:01AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
DJ Beam Therapeutics Is Maintained at Sector Perform by RBC Capital, from 11:10AM ET on Wednesday Nov 06, 2024 by Dow Jones
11:10AM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners, from 7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:39AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Press Release: Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting, from 9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 2.0B | -14.0x | --- |
Genmab A/S | 13.5B | 20.4x | +22.71% |
Galapagos NV | 1.8B | -28.1x | --- |
Catalyst Pharmaceuticals Inc | 2.5B | 17.8x | --- |
BioCryst Pharmaceuticals Inc | 1.5B | -11.6x | --- |
Veracyte Inc | 2.8B | -251.8x | --- |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Principal Financial and Accounting Officer, Director
- John Evans
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
- Lead Independent Director
- Mark Fishman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $349.6M |
Shares Outstanding | 82.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.87 |
EPS | $-1.72 |
Book Value | $12.02 |
P/E Ratio | -14.0x |
Price/Sales (TTM) | 5.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
